News Briefs: September 16, 2019

Black Market Leading Cali Cannabis Sales

This past week, per the Los Angeles Times, the United Cannabis Business Association (UCBA) turned in the findings of an audit on illicit and legal operating cannabis stores to Gov. Gavin Newsom (D- Calif.) that was gathered with the aid of online website WeedMaps. The audit showed that there were 3,757 listings for a marijuana dispensary or cannabis delivery service in California… which is a problem given that only 873 cannabis sellers are licensed in the state. By the UCBA’s estimates, 2,835 of the 3,757 listings on WeedMaps are for unlicensed sellers. Put another way, there are more than three times as many illegal retailers than there are legal dispensaries or delivery services.

Read more

 

New Bill on the Table to Reschedule Marjuana

Rep. Greg Steube (R-FL) introduced the legislation, which is titled the “Marijuana 1-to-3 Act.” True to its name, the bill would simply require the attorney general to move cannabis from Schedule I to Schedule III under the Controlled Substances Act, with the aim of increasing research on the drug’s effects.

Read More

 

Feds Want Lots of Drugs

The Drug Enforcement Administration (DEA) wants 3,200,000 grams of marijuana to be legally grown in the U.S. next year, the agency announced. The more than 7,000 pounds of cannabis will be used in scientific studies investigating the effects of the plant. Separately in the new Federal Register notice, DEA is proposing that 384,460 grams of tetrahydrocannabinols, 40 grams of LSD, 50 grams of MDMA and 30 grams of psilocybin be produced next year.

Read More

 

Is Google Banning CBD Ads?

Google has announced a new policy for speculative and experimental medicines. In its section concerning advertisements, Google shared its new “Healthcare and Medicines” policy.

The new policy prohibits, “advertising for unproven or experimental medical techniques such as most stem cell therapy, cellular (non-stem) therapy, and gene therapy.”

The policy does not explicitly identify CBD, but it does lead to the question as to whether these substances will be excluded under the new policy. After all, at the end of the day, the benefits of CBD is largely dependent upon anecdotal, and not clinical evidence.

Read More

 

Juul Thumbs Nose at FDA

The FDA is hot on the trail of Juul about an ad campaign from the vaping company that recommended consumers switch from regular cigarettes. Is Juul worried? Nah. A company spokesman told CNBC that Juul plans to continue running the commercials and has already bought ads for the next month.

Read More

  • CannaAid and Peak: Something new for everyone.

Recent Articles

As a lifelong stoner, feminist, and teacher, Luna Stower does know how intersectional plant medicine can be.
“Whenever somebody sees ‘Sales Guru’ on my card, they ask how you become one,” he says. “I tell them that you spend your life in sales, and you go to Nepal to climb the Himalayas to meet the real gurus. You get the wisdom from them, then you bring it back down and apply it to your life.”
Cryptocurrency is taking the world by storm. It’s been over 15 years since the launch of Bitcoin, and although it’s more popular than ever before, it’s not the only form of crypto available today.
We know breaking up is hard to do, but sometimes the thrill is gone, and it’s time to move on. It doesn’t matter how long a brand’s been riding with you or how tight you are with the sales rep. If the product doesn’t perform, or worse, if the brand loses touch with the culture, it’s dead weight. And dead weight doesn’t just slow you down; it can drown you.
At HQ, we don’t shy away from controversy, but we also don’t exist to tear down legitimate players in the industry. We chose instead to invite both perspectives to weigh in.
Ali Bianco wants to elevate the cannabis world one pink pre-roll at a time. Since high school, she’s been sick of the stigma around weed and the idea that stoners are lazy and unkempt. Inspired by Blake Lively’s character smoking pink cigarettes in the 2011 film Hick, Ali decided to “make weed something beautiful” with a feminist kick.
In the early days, we bought flower based on two metrics: THC percentage and the vague promise of either indica or sativa. It was like ordering wine based on alcohol content and whether the label showed a beach or a mountain. We’ve come a long way.
I've witnessed firsthand how patient advocacy can profoundly change healthcare and people's lives. Today, I'm honored to lead ASA once again, as we intensify efforts to ensure medical cannabis reaches all patients who need it, fully integrated into our nation's healthcare system.